Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242181 | 0.91 | CCR9 (0.39) | CCR9ALDH1A1LMNANR1H4MEN1 | |
| SCHEMBL1239513 | 0.88 | MMP9 (0.41) | ALDH1A1LMNANR1H4MEN1KMT2A | |
| SCHEMBL1239588 | 0.88 | CCR9 (0.41) | CCR9ALDH1A1LMNANR1H4MEN1 | |
| SCHEMBL1239528 | 0.86 | CCR9 (0.38) | CCR9NR1H4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1242294 | 0.85 | WDR5 (0.40) | CCR9LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1241447 | 0.84 | PTPN1 (0.41) | CCR9NR1H4HDAC8HDAC6PTGER1 | |
| SCHEMBL1241365 | 0.82 | NR1H4 (0.46) | LMNANR1H4MEN1KMT2AHDAC8 | |
| SCHEMBL12953074 | 0.82 | NR1H4 (0.46) | LMNANR1H4MEN1KMT2AHDAC8 | |
| SCHEMBL1242357 | 0.80 | NR1H4 (0.42) | ALDH1A1LMNANR1H4MEN1KMT2A | |
| SCHEMBL1242344 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNANR1H4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2072498-A1 | N-PHENYLOXAMIDIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-06-24 | — | — | EP | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | CCR9 1743/4885ALDH1A1 397/4885LMNA 488/4885 |
| US-20090215899-A9 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | CCR9 1743/4885ALDH1A1 397/4885LMNA 488/4885 |
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | CCR9 1792/4885ALDH1A1 1168/4885LMNA 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.